September marks "National Muscular Dystrophy Awareness Month," an annual observance that raises awareness and drives critical fundraising for families across the nation who are living with muscular dystrophy, ALS, and related neuromuscular diseases.
Researchers have identified a new gene that may increase a person's risk of developing ALS. The gene, called TP73, produces a protein to help regulate the life cycle of a cell.
In some cases of familial ALS, the origin lies in a gene called C9ORF72. But why do mutations in this gene kill motor neurons? The Genomic Instability Group may have found the answer, which they explain in The EMBO Journal.
Target ALS launches The Target ALS Diagnosis Initiative, a comprehensive effort to discover ALS biomarkers. Through the initiative, the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources.
Read More
Congress passed it and now The ALS Disability Insurance Access Act needs only President Trump’s signature to end the 5-month waiting period that stands in the way of benefits.
Read More
Two ALS patients, implanted with the Stentrode brain-computer interface via the jugular vein and without the need for open brain surgery, successfully controlled their personal computer through direct thought, according to a study published in the Journal of NeuroInterventional Surgery.
Read More
Researchers from Massachusetts Institute of Technology (MIT) have designed a skin-like device that can measure small facial movements in patients who have lost the ability to speak. Their study appears in Nature Biomedical Engineering.
Read More
The Muscular Dystrophy Association (MDA) announces the awarding of five new MDA grants totaling more than $1.6 million toward research focused on amyotrophic lateral sclerosis (ALS).
Read More
Together, Target ALS and Spartan have launched “The Toughest Challenge For The Hardest Fight,” a multiyear charitable initiative to raise funds for ALS research.
Read More
The US Food and Drug Administration (FDA) has granted Breakthrough Device designation for Stentrode, an implantable medical device designed to translate brain activity or stimulate the nervous system from the inside of a blood vessel, without the need for open brain surgery, Synchron announces in a media release.
Read More
To celebrate MDA National Muscular Dystrophy Awareness Month in September, the Muscular Dystrophy Association (MDA) is hosting virtual events to raise funds for treatment and care for people affected by muscular dystrophy, ALS, and related neuromuscular disease.
Read More
Researchers demonstrated the success of a fully implantable wireless medical device called a Stentrode Brain-Computer Interface designed to improve functional independence in patients with severe paralysis in an abstract presented recently at the Society of NeuroInterventional Surgery’s (SNIS) 17th Annual Meeting.
Read More
This year, the International Association of Fire Fighters (IAFF) launches its annual Fill the Boot fund-raiser for the Muscular Dystrophy Association (MDA) online to address social distancing guidelines for the firefighters and the vulnerable community MDA serves.
Read More
By sequencing microRNA within exosomes originating in the brain, it is now possible to definitively distinguish blood samples of ALS patients from healthy controls, researchers at the Brain Chemistry Labs report in Royal Society Open Biology.
Read More
The ALS Association and I AM ALS have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics, a biotechnology company, to support an amyotrophic lateral sclerosis (ALS) biomarker research study.
Read More
Mutations in the gene UBQLN2, which regulates the disposal of misfolded “garbage” from the body’s cells, may cause amyotrophic lateral sclerosis (ALS) and may also be responsible for a certain form of dementia related to ALS, researchers suggest.
Read More
A study published recently in eNeuro clarifies the mechanisms underlying neural dysfunction in ALS, and also suggests a novel approach to restoring the health of motor neurons in patients with the disease.
Read More
Restoring the protein SV2 in a genetic form of ALS can correct abnormalities in transmission and even prevent cells from dying, providing a new target for future therapies, according to researchers.
Read More